JAC Advance Access originally published online on September 19, 2005
Journal of Antimicrobial Chemotherapy 2005 56(5):841-846; doi:10.1093/jac/dki327
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
mef(A), mef(E) and a new mef allele in macrolide-resistant Streptococcus spp. isolates from Norway
1 Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology, University Hospital of North Norway (UNN) and Department of Microbiology and Virology, Institute of Medical Biology, Faculty of Medicine, University of Tromsø, N-9037 Tromsø, Norway; 2 Division of Infectious Disease Control, Norwegian Institute of Public Health, Pb 4404 Nydalen, N-0403 Oslo, Norway
Received 22 June 2005; returned 27 July 2005; revised 12 August 2005; accepted 17 August 2005
* Corresponding author. Tel: +47-77-64-62-02; Fax: +47-77-64-53-50; E-mail: arnfinns{at}fagmed.uit.no
Objectives: To type mef genes in a nationwide collection of clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes as well as pharyngeal carrier strains of viridans streptococci in Norway.
Methods: Erythromycin-resistant mef-positive multilocus sequence-typed (MLST) clinical isolates of S. pneumoniae (n = 36) and S. pyogenes (n = 12) from the National Surveillance Program for Antimicrobial Resistance (NORM) as well as viridans streptococci (n = 20) from healthy adults were included. PCR-amplified mef genes were initially discriminated by BamHI digestion. Selected mef genes from representatives of different sequence types (STs) of S. pneumoniae (n = 11) and S. pyogenes (n = 4), and viridans group streptococcal species (n = 8) were typed by sequencing and their strains examined for co-resistances. Hydropathy plots of different mef-encoded proteins were performed.
Results: A predominance of mef(A) was detected in S. pneumoniae (23/36) and S. pyogenes (9/12) due to the clonal spread of ST9 and ST39, respectively. mef(E) was the most widely distributed mef determinant occurring in nine different STs of S. pneumoniae and in four different viridans species. A new mef allele was identified in two STs of S. pyogenes.
Conclusions: mef(E) is the most widely distributed mef determinant in Norwegian clinical strains of S. pneumoniae and pharyngeal carrier strains of various viridans streptococci. However, mef(A) is more prevalent in S. pneumoniae and S. pyogenes due to clonal spread. A new mef allele was found in two different STs of S. pyogenes.
Keywords: macrolide efflux , erythromycin , M-type resistance , Major Facilitator Superfamily
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Blackman Northwood, M. Del Grosso, L. R. Cossins, M. D. Coley, R. Creti, A. Pantosti, and D. J. Farrell Characterization of Macrolide Efflux Pump mef Subclasses Detected in Clinical Isolates of Streptococcus pyogenes Isolated between 1999 and 2005 Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1921 - 1925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Siira, M. Rantala, J. Jalava, A. J. Hakanen, P. Huovinen, T. Kaijalainen, O. Lyytikainen, and A. Virolainen Temporal Trends of Antimicrobial Resistance and Clonality of Invasive Streptococcus pneumoniae Isolates in Finland, 2002 to 2006 Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2066 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Varaldo, M. P. Montanari, and E. Giovanetti Genetic Elements Responsible for Erythromycin Resistance in Streptococci Antimicrob. Agents Chemother., February 1, 2009; 53(2): 343 - 353. [Full Text] [PDF]
|
|
|
|
|
|
M. Mingoia, M. Vecchi, I. Cochetti, E. Tili, L. A. Vitali, A. Manzin, P. E. Varaldo, and M. P. Montanari Composite Structure of Streptococcus pneumoniae Containing the Erythromycin Efflux Resistance Gene mef(I) and the Chloramphenicol Resistance Gene catQ Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3983 - 3987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. V. Hawkyard and R. J. Koerner The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks J. Antimicrob. Chemother., March 1, 2007; 59(3): 347 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kosowska-Shick, K. Smith, T. Bogdanovich, L. M. Ednie, R. N. Jones, and P. C. Appelbaum Activity of DX-619 Compared to Other Agents against Viridans Group Streptococci, Streptococcus bovis, and Cardiobacterium hominis Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4191 - 4194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Del Grosso, R. Camilli, F. Iannelli, G. Pozzi, and A. Pantosti The mef(E)-Carrying Genetic Element (mega) of Streptococcus pneumoniae: Insertion Sites and Association with Other Genetic Elements. Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3361 - 3366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Robinson, J. A. Sutcliffe, W. Tewodros, A. Manoharan, and D. E. Bessen Evolution and global dissemination of macrolide-resistant group a streptococci. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2903 - 2911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Littauer, D. A. Caugant, M. Sangvik, E. A. Hoiby, A. Sundsfjord, G. S. Simonsen, and the Norwegian Macrolide Study Group Macrolide-Resistant Streptococcus pyogenes in Norway: Population Structure and Resistance Determinants. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1896 - 1899. [Abstract] [Full Text] [PDF]
|
|